The research progress of direct KRAS G12C mutation inhibitors
A Yang, M Li, M Fang - Pathology & Oncology Research, 2021 - por-journal.com
A Yang, M Li, M Fang
Pathology & Oncology Research, 2021•por-journal.comKRAS mutations have long been considered undruggable. However, a series of direct KRAS
mutation inhibitors have been developed since the switch II pocket was discovered recently.
This review will summarize progress in the development of direct KRAS G12C mutation
inhibitors, current relevant drugs under study and challenges that need to be considered in
future research.
mutation inhibitors have been developed since the switch II pocket was discovered recently.
This review will summarize progress in the development of direct KRAS G12C mutation
inhibitors, current relevant drugs under study and challenges that need to be considered in
future research.
Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.
por-journal.com
